TTIPF (Thiogenesis Therapeutics) FCF Margin %: 0.00% (As of Mar. 2026)


TTIPF Thiogenesis Therapeutics Corp TTIPF
12 GF Score
Price $0.42
! 1 Warning Sign
View Full Analysis

What is Thiogenesis Therapeutics FCF Margin %?

Thiogenesis Therapeutics TTIPF -6.67% 12 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates TTIPF with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 959 Biotechnology companies, Thiogenesis Therapeutics ranks worse than 104275.18% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Thiogenesis Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-0.52 Mil. Thiogenesis Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Thiogenesis Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Thiogenesis Therapeutics's current FCF Yield % is -20.36%.

The historical rank and industry rank for Thiogenesis Therapeutics's FCF Margin % or its related term are showing as below:


TTIPF's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -84.65
* Ranked among companies with meaningful FCF Margin % only.

Thiogenesis Therapeutics FCF Margin % Related Terms

Thiogenesis Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Thiogenesis Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thiogenesis Therapeutics FCF Margin % Chart

Thiogenesis Therapeutics Annual Data
Trend Dec19 Dec20 Feb21 Feb22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Thiogenesis Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TTIPF vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Thiogenesis Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Thiogenesis Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thiogenesis Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Thiogenesis Therapeutics's FCF Margin % falls into.


TTIPF
12GF Score
Thiogenesis Therapeutics Corp TTIPF
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thiogenesis Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Thiogenesis Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-4.373/0
= %

Thiogenesis Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-0.515/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Thiogenesis Therapeutics (TTIPF) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Thiogenesis Therapeutics and its competitors. According to the industry distribution chart, Thiogenesis Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry.
Is Thiogenesis Therapeutics' FCF Margin % too high?
Thiogenesis Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Thiogenesis Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Thiogenesis Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Thiogenesis Therapeutics' FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Thiogenesis Therapeutics ranks #999999 out of 959 companies for FCF Margin %. This places Thiogenesis Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Thiogenesis Therapeutics and its competitors. Thiogenesis Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thiogenesis Therapeutics stock overvalued right now?
Thiogenesis Therapeutics (TTIPF) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Thiogenesis Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Thiogenesis Therapeutics (TTIPF), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Thiogenesis Therapeutics Business Description

Other Exchanges Q8M:GermanyTTI:Canada
Address 4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6
Thiogenesis Therapeutics Corp is a clinical-stage biotechnology company developing TTI-0102, a novel controlled-release cysteamine prodrug designed to improve tolerability and dosing relative to existing therapies. The Company is focused on TTI-0102 in nephropathic cystinosis, where it is in late-stage development, and is also conducting research and clinical development activities for primary mitochondrial diseases, including Leigh syndrome spectrum disorders.
12GF Score

Get the complete analysis for TTIPF

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price